KLOW is a multi-compound research blend formulated as a single 80mg vial combining GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg), commonly studied in preclinical models for copper-binding/ECM signaling, cytoskeletal dynamics, and inflammatory-pathway marker analysis.
Highlights:
Components: